Macrophage activation and inflammatory priming by anti-MAA antibodies in rheumatoid arthritis.

Anti-MAA Autoantibody Inflammation Macrophage Rheumatoid arthritis Risk RA phase

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
03 Jul 2024
Historique:
received: 28 03 2024
revised: 13 06 2024
accepted: 27 06 2024
medline: 6 7 2024
pubmed: 6 7 2024
entrez: 5 7 2024
Statut: aheadofprint

Résumé

We studied the effects of rheumatoid arthritis (RA) autoantibodies that target malondialdehyde-acetaldehyde protein adducts (anti-MAA) on inflammation and macrophage functions. We detected a profound reprogramming of gene expressions and the production of chemokines, such as CCL22 and CCL24, in anti-MAA exposed macrophages. Moreover, anti-MAA pretreatment promoted a more inflammatory cytokine profile upon TLR activation. Although anti-MAA are typically multi-reactive, we observed a prominent clonal diversity in inducing macrophage activation. Anti-MAA antibodies were not arthritogenic in mice, but altered a set of cytokine and growth factor encoding genes in the joints. In individuals at risk of RA anti-MAA IgG levels correlated with circulating inflammatory mediators prior to and at arthritis onset. Certain IgG anti-MAA clones may thus contribute to an inflammatory priming of the joint prior to the onset of systemic inflammation via inducing FcγR-mediated macrophage pre-activation and setting the stage for augmented responses to subsequent inflammatory stimuli.

Identifiants

pubmed: 38969267
pii: S1521-6616(24)00412-1
doi: 10.1016/j.clim.2024.110303
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110303

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no competing interests.

Auteurs

Marcelo Afonso (M)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden.

Jitong Sun (J)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden.

Koji Sakuraba (K)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden; Department of Orthopedic Surgery and Rheumatology, Clinical Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka. Japan.

Alexandra Cîrciumaru (A)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden; Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Region Stockholm, Sweden.

Denis Lagutkin (D)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden.

Masa Filipovic (M)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden.

Anca I Catrina (AI)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden; Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Region Stockholm, Sweden; Department of Rheumatology, Karolinska University Hospital, Sweden.

Caroline Grönwall (C)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden.

Aase Hensvold (A)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden; Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Region Stockholm, Sweden.

Bence Réthi (B)

Division of Rheumatology, Department of Medicine Solna. Karolinska Institutet, Stockholm, Sweden. Electronic address: rethi@ki.se.

Classifications MeSH